Ascendis Announces Oral Presentation of Week 104 Data from Its Pivotal Trial of TransCon® CNP (Navepegritide) at ISDS 2026

ConferenceTransCon CNPPositive

AI Analysis

Summary

Ascendis Pharma will present Week 104 data from its pivotal ApproaCH Trial of TransCon CNP (navepegritide) in children with achondroplasia at the ISDS 2026 annual meeting in Toronto. The oral presentation will be delivered by Dr. Carlos Bacino from Baylor College of Medicine.

Clinical Trial Data

Outcome Details

Week 104 data from pivotal ApproaCH Trial presented at ISDS 2026

Importance:5/10

Sentiment:

0.30

conference presentationclinical datapivotal trialachondroplasiarare disease

Related Companies

$ASND

Read the original article

Published by GlobeNewswire Pharma on August 25, 2026 8:01 PM

Read Original